FAQ: Define, compare, and contrast humoral and cell-mediated immunity.
GHAPPcast4 Joulu 2024

FAQ: Define, compare, and contrast humoral and cell-mediated immunity.

Thank you to Johnson & Johnson for your support of this FAQ Video Module.

In this FAQ video module, Erica Heagy, NP, from Alaska Digestive and Liver Disease, breaks down the key differences between humoral immunity and cell-mediated immunity, two crucial components of the adaptive immune system that protect the body from infections.

Adaptive immunity is triggered when the body is exposed to antigens, allowing it to mount a targeted defense against viruses, bacteria, and toxins. Within this system, humoral and cell-mediated immunity function in distinct but complementary ways.

Humoral immunity, also known as antibody-mediated immunity, is driven by B cells, which produce antibodies to neutralize extracellular pathogens such as bacteria and toxins. This response develops rapidly, offering quick protection, but it tends to be shorter-lasting compared to cellular immunity.

In contrast, cell-mediated immunity is primarily led by T cells and plays a crucial role in combating intracellular pathogens, including virus-infected cells. This response takes longer to activate, but it provides long-term protection by directly targeting and eliminating infected cells.

Understanding the balance between humoral and cellular immunity is essential in infectious disease management, vaccine development, and autoimmune disorder research. A strong grasp of these immune responses helps healthcare providers make informed decisions about treatments, immunotherapies, and disease prevention strategies.

For more information on immune system functions, immunotherapy, and advancements in gastroenterology, visit GHAPP.org or download the GHAPP ACE app on IOS and Android. Follow us on LinkedIn, YouTube, X (Twitter), and Instagram for expert insights and updates.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(161)

GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy

GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy

Thank you to Salix for their support on this podcast episode. In this GHAPP podcast, host Christina Hanson, FNP, welcomes Janet Gripshover, DNP, FNP-BC, MBA, for a practical discussion on recognizing ...

18 Elo 48min

FAQ: Counseling Patients on Overt Hepatic Encephalopathy

FAQ: Counseling Patients on Overt Hepatic Encephalopathy

Thank you to Salix for their support on this FAQ video module.In this FAQ video module, Natalie Oliver, PA-C, discusses how healthcare professionals can counsel patients and caregivers about overt hep...

11 Elo 4min

FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy

FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy

Thank you to Salix for their support on this FAQ video module. In this FAQ video module, Samantha Ramirez, NP-C, discusses how healthcare professionals can identify and diagnose overt hepatic encephal...

4 Elo 2min

Subgroup Analysis: Differences in Maintenance Dosing For UC and CD

Subgroup Analysis: Differences in Maintenance Dosing For UC and CD

Thank you to Johnson & Johnson for their support on this podcast episode. In this GHAPP podcast, Amy Stewart, NP, of Capital Digestive Care, introduces a practical inflammatory bowel disease discussio...

23 Heinä 7min

Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC

Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC

Thank you to AbbVie for their support of this Medication Review Video Module.In this medication review, Melissa Ferrari, PA, and Jennifer Hamilton, MSPAS, PA-C, provide a comprehensive overview of the...

30 Kesä 17min

Med Review: SEQUENCE Trial: Risankizumab vs Ustekinumab in Anti-TNF-Refractory Crohn’s Disease

Med Review: SEQUENCE Trial: Risankizumab vs Ustekinumab in Anti-TNF-Refractory Crohn’s Disease

Thank you to AbbVie for their support on this Medication Review Video Module. In this medication review, Sharon Dudley-Brown, CRNP, PhD from Johns Hopkins University and Angelina Collins, MSN, ANP-BC,...

9 Kesä 12min

FAQ: QUASAR Long Term Extension Interim Analysis

FAQ: QUASAR Long Term Extension Interim Analysis

Thank you to Johnson & Johnson for their support on this FAQ Video Module. In this educational video, Jamie Brogan, APRN, from Northwestern Medicine, reviews the latest QUASAR long-term extension data...

2 Kesä 4min

Medication Review: Guselkumab IV vs SC Formulation

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory...

28 Touko 3min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
tiedenaiset-podcast
rss-pitaisko-erota
psykopodiaa-podcast
vakeva-elama-viisaampi-mieli-vahvempi-keho
voi-hyvin-meditaatiot-2
paritellen
terapiassa
meditaatiot-suomeksi
rss-pt-paahtio
rss-seksicast
rss-vapaudu-voimaasi
rss-kuumilla-aalloilla
selviytyjat-tarinoita-elamasta
rss-mighty-finland-podcast
rss-uplevel-by-sonja-hannus
ruokaklinikka
junnut-pelissa
leikitaanko-laakaria
katilon-kahvitunti